



News Release

Notice regarding Shire shareholder approvals at the Shire Court Meeting and General Meeting

Osaka, Japan, December 6, 2018 - In relation to the proposed acquisition (the "Acquisition") of Shire plc ("Shire"), Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") hereby announces that on December 5, 2018 (GMT) at: (i) a meeting of Shire shareholders convened by order of the Royal Court of Jersey (the "Court Meeting"); and (ii) a general meeting of Shire shareholders (the "Shareholder Meeting"), Shire's shareholders voted to approve the Shire Scheme of Arrangement (the "Scheme") to be implemented in connection with the Acquisition and certain other related matters.

As a result of the Shire shareholder approvals having been obtained, the conditions to the Acquisition relating to Shire shareholder approval (as outlined in Takeda's announcement entitled "Agreement on Commencement of a Friendly Acquisition Procedure to Make Shire plc a Wholly-owned Subsidiary" on May 8, 2018) have now been satisfied.

The Acquisition is expected to be completed on January 8, 2019, subject to certain conditions including the sanctioning of the Scheme by the Royal Court of Jersey at a hearing expected to be held on January 3, 2019.

###